8:00 - 8:15 am  Welcome and Approval of 2017 Spring Meeting Minutes  
T. Petrella

8:15 - 8:40 am  Rapid Trial Updates (awaiting analysis or recently closed)  

• MEC.3 - A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma (ECOG)  
T. Petrella

• MEC.4 – Randomized Phase II Study Comparing the Met Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma (Alliance)  
M. Butler

• MEC.5 – A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma (SWOG)  
T. Petrella

• IND225 – A Phase II Study of the Assessment of Response To Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker  
T. Petrella

• IND228 – A Phase II Study of Dervalumab and Tremelimumab in patients with advanced rare tumours  
J. Dancey

8:40 - 9:15 am  Trial Updates (ongoing / planned)  

• IND224 – A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases  
T. Petrella

• ME13 – A Randomized Phase III Study of Duration of Anti-PD1 Therapy in Metastatic Melanoma (STOP-GAP)  
Tara Baetz/ Xinni Song

• ME14 - Prophylactic mesalamine to reduce immune-related AEs with combination ipilimumab / nivolumab in metastatic melanoma  
J. Walker
9:15 – 9:45 am  **Review of Melanoma Strategy / Priorities and Terms of Reference**  J. Dancey

9:45 - 10:00 am  **Break**

10:00 - 11:00 am  **New Proposals / Updates**

- PILOT Update on the Melanoma Margins Trial (MelMarT): F. Wright
  A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

- The Terry Fox Research Institute Marathon of Hope Proposal  Ian Watson

- EA6134: Dabrafenib and Trametinib followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab followed by Dabrafenib and Trametinib in treating patients with stage III-IV BRAFV600 Melanoma  T. Petrella

- Neoadjuvant Trial Concept  T. Petrella

- ALLIANCE meeting at ASCO  M. Butler

11:00 - 12:00 pm  **Novartis Pipeline**  Bijoyesh Mookerjee  
Senior Global Program Clinical Head

12:00 pm  **Meeting Adjourned**

12:00 - 1:00 pm  **Executive Committee meeting to follow (closed)**